Blastic plasmacytoid dendritic cell neoplasm

From - A Hematology Oncology Wiki
(Redirected from BPDCN)
Jump to navigation Jump to search
Section editor
Martin W. Schoen, MD, MPH
Saint Louis University
St. Louis, MO

Social-twitter-icon.png mwschoen
1 regimens on this page
1 variants on this page

All lines of therapy

Tagraxofusp monotherapy

back to top


Study Years of enrollment Evidence
Frankel et al. 2014 (STU 012013-061) 2013-NR Phase I/II, <20 pts
Pemmaraju et al. 2019 (STML-401-0114) 2014-2017 Phase I/II (RT)

Targeted therapy

21-day cycles


  1. STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article PubMed NCT00397579
  2. STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article contains verified protocol PubMed NCT02113982